FMI - Foundation Medicine, Inc.

YHD - YHD Delayed Price. Currency in USD
At close: 6:07PM EDT
Stock chart is not supported by your current browser
Previous CloseN/A
YTD ReturnN/A
Expense Ratio (net)N/A
Last Cap GainN/A
Morningstar RatingN/A
Morningstar Risk RatingN/A
Sustainability RatingN/A
Net AssetsN/A
Beta (3Y Monthly)N/A
5y Average ReturnN/A
Holdings TurnoverN/A
Last DividendN/A
Average for CategoryN/A
Inception DateN/A
  • Reuters10 months ago

    With new blood test, Roche dives deeper into personal cancer care

    Swiss drugmaker Roche upped its bet on personalised cancer treatment on Monday, saying it is now ready to sell a blood test around the world that can identify common gene mutations from solid tumours from a patient's blood. The blood test, called FoundationOne Liquid, is among initial products to emerge from Foundation Medicine after Roche spent $2.4 billion on the U.S.-based genetic profiling company this year on the conviction that future cancer treatment will be tailored to individual characteristics of a patient's tumour.

  • Incyte, Foundation Medicine Partner for Companion Diagnostics
    Zacks10 months ago

    Incyte, Foundation Medicine Partner for Companion Diagnostics

    Incyte (INCY) inks an agreement with Foundation Medicine for the development of companion diagnostics (CDx) for Incy's selective FGFR Inhibitor, pemigatinib.

  • Business Wirelast year

    Foundation Medicine Publishes New Data in Nature Medicine Supporting Blood Tumor Mutational Burden (bTMB) as a Novel Predictor of Response to Cancer Immunotherapy

    Foundation Medicine, today announced the publication of the results of a large study demonstrating that its novel, investigational assay to measure blood tumor mutational burden (bTMB) can help predict response to the anti-PD-L1 immunotherapy, atezolizumab, (TECENTRIQ®) in patients with previously treated non-small cell lung cancer (NSCLC). The study, published in the journal Nature Medicine, was the result of a collaboration between Foundation Medicine and Genentech, a member of the Roche Group, and demonstrates the potential of bTMB to expand precision oncology approaches for patients with advanced cancers, including metastatic lung cancer. In addition, these results show that bTMB may be an independent predictor of clinical benefit, regardless of PD-L1 expression as assessed by immunohistochemistry.

  • GlobeNewswirelast year

    Roche Purchases Shares in Tender Offer for FMI

    OTCQX: RHHBY) and Foundation Medicine, Inc. (FMI) today announced that Roche`s wholly owned subsidiary 062018 Merger Subsidiary, Inc. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of Foundation Medicine not already owned by Roche or its affiliates, at a price of $137.00 per share in cash. The tender offer expired at 12:00 midnight, Eastern Time, at the end of the day on 30 July 2018 and was not extended.

  • ACCESSWIRElast year

    Breakfast Technical Briefing on TrovaGene and Three Other Additional Medical Research Stocks

    LONDON, UK / ACCESSWIRE / July 27, 2018 / If you want a free Stock Review on TROV sign up now at draws investors' attention to the Medical Laboratories and Research category, which includes companies that focus on performing various tests on patients that give them information on patients' health. Lined up for review are the following equities: Foundation Medicine Inc. (NASDAQ: FMI), NeoGenomics Inc. (NASDAQ: NEO), Neuronetics Inc. (NASDAQ: STIM), and TrovaGene Inc. (NASDAQ: TROV).